Using continuous glucose monitoring in kidney transplant recipients with diabetes
Continuous Glucose Monitoring (CGM) to Improve Glycemic Control in Kidney Transplant Recipients
This study is testing if using a continuous glucose monitor can help kidney transplant recipients with Type 2 diabetes keep their blood sugar levels more stable.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, Davis Academic / other |
| Locations | 1 site (Sacramento, California) |
| Trial ID | NCT04783441 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of continuous glucose monitoring (CGM) on glycemic control in kidney transplant recipients who have Type 2 diabetes. The focus is on measuring time in range (TIR) for blood glucose levels between 70-180 mg/dL, which is crucial for managing diabetes post-transplant. Participants will use the Dexcom G6 device to track their glucose levels, allowing for better medication titration and management of glycemic variability. The study aims to address the challenges of maintaining glycemic control in the context of complex medication regimens and post-operative recovery.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have received a kidney transplant within the past year and have Type 2 diabetes requiring insulin.
Not a fit: Patients with Type 1 diabetes or those with significant cognitive or visual impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve glycemic control and overall health outcomes for kidney transplant recipients with diabetes.
How similar studies have performed: Previous studies have shown promising results with continuous glucose monitoring in diabetic populations, suggesting potential success for this approach in kidney transplant recipients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 or above 2. Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min 3. Person with Type 2 Diabetes and on insulin 4. Access to home wi-fi connection Exclusion Criteria: 1. Person with Type 1 Diabetes 2. Patients taking hydroxyurea 3. Patient unable to wear the Dexcom G6 device at all times for any reason 4. Must be able to test blood glucose with meter 4x a day when on blinded CGM. 5. Presence of clinically significant visual or cognitive impairment 6. Illiterate 7. Prisoners 8. Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding 9. Presence of clinically unstable cardiovascular disease 10. Active malignancy treatment
Where this trial is running
Sacramento, California
- UC Davis Health — Sacramento, California, United States (Recruiting)
Study contacts
- Study coordinator: Dahlia Zuidema, PharmD
- Email: dmzuidema@ucdavis.edu
- Phone: 916-734-4009
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.